AiCure develops AI-driven software and analytics to enhance patient engagement, digital biomarkers, and sponsor insights in clinical trials. The company’s platform is positioned to improve monitoring and outcomes for life‑science sponsors running trials. In 2023 AiCure was granted seven new U.S. patents, bringing its total U.S. patent count to 86, with additional patents issued globally. On January 25, 2024, AiCure completed a $12M loan refinancing and raised an additional $4M+ from existing investors. The company said the proceeds will be used to invest in research and development, expand operations, and enhance its products and services. AiCure also added two senior hires: Sondra Pepe as SVP of Product Management and Josh Wilson as SVP of Operations. AiCure is an AI-driven healthcare platform that uses artificial intelligence to see, hear and understand how people respond to treatment in clinical trials and patient care. Its technologies are clinically proven to measure and modify patient behavior, helping keep patients engaged and optimized for treatment and to evaluate treatment effectiveness. The company holds more than 100 registered patents and works with global clients in more than 25 countries. AiCure was founded in 2010 and is led by CEO Adam Hanina. The company is based in New York City. It raised $24.5M in a Series C and intends to use the funds to accelerate its business activities. AiCure offers a mobile software-as-a-service platform that uses machine learning, computer vision, and big data to visually confirm patients’ medication ingestion. The technology has been validated against drug levels in blood samples and across patient populations including elderly stroke patients and participants in schizophrenia and HIV prevention trials. AiCure partners with pharmaceutical companies and government institutions to monitor medication adherence and optimize treatment models. The company is led by CEO Adam Hanina and operates from New York City. Financially, AiCure completed a Series A financing to support its operations and partnerships. The platform targets clinical-trial and treatment-adherence use cases through its AI-driven verification and monitoring capabilities.

Total raised

$53M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Jan 2024